Strand Life Sciences launches South Asia’s first Olink Explore HT Proteomics service for advanced multi-omics research
Babushahi Bureau
Bengaluru (Karnataka), May 20, 2026 — Strand Life Sciences, a subsidiary of Reliance Industries Limited, has announced the launch of South Asia’s first Olink™ Explore HT proteomics service, aimed at accelerating large-scale multi-omics research and precision medicine in the region.
The company said the advanced platform will allow researchers to analyse more than 5,400 protein biomarkers using an extremely small blood sample, helping scientists gain deeper insights into diseases and treatment responses.
Proteomics is the large-scale study of proteins, which are responsible for carrying out vital biological functions in the human body. Scientists say analysing proteins can provide a clearer understanding of how diseases develop and progress, making it a powerful tool for drug discovery and personalised treatment.
According to the company, the newly launched Olink™ Explore HT technology can measure thousands of proteins from just 2 microlitres of sample — a fraction of a single drop of blood. The platform will enable Strand Life Sciences to combine proteomics data with genomics and clinical information to support advanced medical research.
As part of the rollout, the company has already completed a proteomics project for a biopharma partner involving patients suffering from chronic kidney disease, showcasing the platform’s application in translational and clinical research.
Ramesh Hariharan, CEO of Strand Life Sciences, said the launch brings one of the world’s most advanced proteomics technologies to India and South Asia. He added that the company aims to strengthen research collaborations with global pharmaceutical and biotechnology firms to speed up scientific discoveries and drug development.
The company stated that the platform would support research across therapeutic areas including oncology, nephrology, metabolic disorders and rare diseases through collaborations with hospitals and clinical partners across India, South Asia and West Asia.
Strand Life Sciences also said it would offer end-to-end support for research programmes, including study design, data analysis and interpretation, while integrating proteomics with genomics and clinical datasets.
For more information, visit Strand Life Sciences